Drug intelligence / Profile preview

vs-01-aclf

Development stage: Unknown
Lead developer: Genfit
Modality: Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intraperitoneal

Overview

VS-01 is a sterile, white liposomal suspension containing citric acid developed as peritoneal dialysis fluid for the treatment of acute-on-chronic liver failure (ACLF), hepatic encephalopathy, ascites, organic acidemia disorder (OAD), and urea cycle disorders such as hyperammonemia. It is administered intraperitoneally via a standard flexible tube used for paracentesis. The drug acts by enhancing the clearance of ammonia and other toxic metabolites from the body through its liposomal formulation[1][2][5]. It is currently in clinical development by Genfit and Versantis AG.

Beyond the preview

Go deeper on vs-01-aclf.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vs-01-aclf.

Explore the full profile